Reinventing Drug Development and Regulatory Affairs through Artificial Intelligence
Abstract
Drug discovery, development, and regulatory approval are traditionally lengthy, costly, and high-risk processes within the pharmaceutical industry. The integration of Artificial Intelligence (AI) offers a transformative approach to overcoming these challenges by enabling data-driven, efficient, and predictive decision-making across the drug development lifecycle. This thesis explores the role of AI technologies, including machine learning, deep learning, and natural language processing, in revolutionizing early drug discovery, preclinical and clinical development, and regulatory affairs. AI-driven methods enhance target identification, lead optimization, clinical trial design, and safety monitoring while reducing development timelines and costs. Furthermore, the study examines the growing application of AI in regulatory processes such as automated dossier review, risk assessment, and pharmacovigilance. Overall, this work highlights AI as a key enabler in modernizing pharmaceutical innovation and regulatory frameworks, ultimately improving the delivery of safe and effective therapies to patients.
Conclusion: The rapid advancement of Artificial Intelligence is fundamentally transforming drug development and regulatory affairs by addressing long-standing challenges related to time, cost, and high failure rates. AI-driven approaches enable more accurate target identification, efficient lead optimization, improved preclinical predictions, and smarter clinical trial design, ultimately enhancing decision-making across the pharmaceutical value chain. In parallel, the adoption of AI in regulatory affairs is modernizing submission processes, risk assessment, and post-marketing surveillance, leading to improved compliance, transparency, and patient safety.
Downloads
References
https://pubmed.ncbi.nlm.nih.gov/19132802/
2. Todeschini R, Consonni V. Molecular descriptors: theory and applications. Weinheim: Wiley-VCH; 2009.
3. Miner G, Elder J, Fast A, Hill T, Nisbet R, Delen D. Practical text mining and statistical analysis for non-structured text data applications. Oxford: Academic Press; 2012.
4. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem [Internet]. 2014 Jun 12 [cited 2026 Mar 17];57(12):4977–5010. Available from:
https://pubmed.ncbi.nlm.nih.gov/24351051/
5. Greene CS, Penrod NM, Kiralis J, Moore JH. Exploiting genetic interactions in network biology. Nat Rev Genet [Internet]. 2015 Jul [cited 2026 Mar 17];16(7):409–423. Available from:
https://pubmed.ncbi.nlm.nih.gov/26007769/
6. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature [Internet]. 2015 May 28 [cited 2026 Mar 17];521(7553):436–444. Available from:
https://pubmed.ncbi.nlm.nih.gov/26017442/
7. Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today [Internet]. 2015 Mar [cited 2026 Mar 17];20(3):318–331. Available from:
https://pubmed.ncbi.nlm.nih.gov/25448759/
8. Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, et al. Social media mining for adverse drug event detection. J Biomed Inform [Internet]. 2015 Apr [cited 2026 Mar 17];54:202–212. Available from:
https://pubmed.ncbi.nlm.nih.gov/25655292/
9. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from:
https://pubmed.ncbi.nlm.nih.gov/26928437/
10. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from:
https://pubmed.ncbi.nlm.nih.gov/26928437/
11. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. Large-scale comparison of machine learning methods for drug target prediction. Chem Res Toxicol [Internet]. 2016 Feb [cited 2026 Mar 17];29(2):154–163. Available from:
https://pubmed.ncbi.nlm.nih.gov/26740092/
12. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today [Internet]. 2018 Jun [cited 2026 Mar 17];23(6):1241–1250. Available from:
https://pubmed.ncbi.nlm.nih.gov/29366762/
13. Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C, Pappu AS, et al. MoleculeNet: a benchmark for molecular machine learning. Chem Sci [Internet]. 2018 Jan [cited 2026 Mar 17];9(2):513–530. Available from:
https://pubmed.ncbi.nlm.nih.gov/29629118/
14. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. Nat Biotechnol [Internet]. 2018 Jan [cited 2026 Mar 17];36(1):15–23. Available from:
https://pubmed.ncbi.nlm.nih.gov/29227477/
15. Mesko B. The guide to artificial intelligence in healthcare. CreateSpace Independent Publishing; 2018.
16. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov [Internet]. 2019 Jun [cited 2026 Mar 17];18(6):463–477. Available from:
https://www.semanticscholar.org/paper/The-rise-of-deep-learning-in-drug-discovery.-Chen-Engkvist/89213307256d538942fab6b4ac7ab0dee6936582
17. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from:
https://pubmed.ncbi.nlm.nih.gov/30617339/
18. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci [Internet]. 2019 Aug [cited 2026 Mar 17];40(8):577–591. Available from:
https://pubmed.ncbi.nlm.nih.gov/31328863/
19. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from:
https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
20. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci [Internet]. 2019 Aug [cited 2026 Mar 17];40(8):577–591. Available from:
https://www.fda.gov/media/167973/download
21. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from:
https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
22. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science [Internet]. 2019 Oct [cited 2026 Mar 17];366(6464):447–453. Available from:
https://pubmed.ncbi.nlm.nih.gov/31649194/
23. Rudin C. Stop explaining black-box machine learning models for high-stakes decisions and use interpretable models instead. Nat Mach Intell [Internet]. 2019 May [cited 2026 Mar 17];1(5):206–215. Available from:
https://www.nature.com/articles/s42256-019-0048-x
24. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from:
https://pubmed.ncbi.nlm.nih.gov/30617339/
25. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today [Internet]. 2019 Mar [cited 2026 Mar 17];24(3):773–780. Available from:
https://www.sciencedirect.com/science/article/abs/pii/S1359644619301849
26. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. 2019 Jan [cited 2026 Mar 17];25(1):44–56. Available from:
https://pubmed.ncbi.nlm.nih.gov/30617339/
27. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov [Internet]. 2019 Jun [cited 2026 Mar 17];18(6):463–477. Available from:
https://pubmed.ncbi.nlm.nih.gov/30976107/
28. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MV, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol [Internet]. 2019 Sep [cited 2026 Mar 17];37(9):1038–1040. Available from:
https://pubmed.ncbi.nlm.nih.gov/31477816/
29. Woodcock J, et al. Innovative regulatory science approaches. Clin Pharmacol Ther [Internet]. 2020 Jan [cited 2026 Mar 17];107(Suppl 1):7–12. Available from:
https://pubmed.ncbi.nlm.nih.gov/31925877/
30. Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol [Internet]. 2020 Sep [cited 2026 Mar 17];38(9):1128–1131. Available from:
https://pubmed.ncbi.nlm.nih.gov/32839510/
31. European Medicines Agency. Regulatory science strategy to 2025 [Internet]. Amsterdam: EMA; 2020 [cited 2026 Mar 17]. Available from:
https://www.ema.europa.eu/en/about-us/what-we-do/regulatory-science-strategy-2025
32. European Medicines Agency. Regulatory science strategy to 2025 [Internet]. Amsterdam: EMA; 2020 [cited 2026 Mar 17]. Available from:
https://www.ema.europa.eu/en/about-us/what-we-do/regulatory-science-strategy-2025
33. IQVIA Institute. The use of artificial intelligence in clinical trials [Internet]. Durham (NC): IQVIA; 2020 [cited 2026 Mar 17]. Available from:
https://www.iqvia.com/insights/the-iqvia-institute/reports/the-use-of-ai-in-clinical-trials
34. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf [Internet]. 2021 Feb [cited 2026 Mar 17];44(2):125–132. Available from:
https://pubmed.ncbi.nlm.nih.gov/33387379/
35. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what’s realistic, what are illusions? Drug Discov Today [Internet]. 2021 Feb [cited 2026 Mar 17];26(2):511–524. Available from:
https://pubmed.ncbi.nlm.nih.gov/33232777/
36. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature [Internet]. 2021 Aug [cited 2026 Mar 17];596(7873):583–589. Available from:
https://pubmed.ncbi.nlm.nih.gov/34265844/
37. Organisation for Economic Co-operation and Development. AI in health care [Internet]. Paris: OECD Publishing; 2021 [cited 2026 Mar 17]. Available from:
https://www.oecd.org/health/ai-in-health.htm
38. U.S. Food and Drug Administration. Artificial intelligence and machine learning in software as a medical device: discussion paper [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 Mar 17]. Available from:
https://www.fda.gov/media/167973/download
39. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ [Internet]. 2016 May [cited 2026 Mar 17];47:20–33. Available from:
https://pubmed.ncbi.nlm.nih.gov/26928437/
40. Price WN, Cohen IG. Privacy in the age of medical AI. Duke Law J. 2019;69(1):46–116
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
